Guidelines for Use of Dornase Alfa (Pulmozyme)®

**Recommended Neonatal Dose, Route, and Interval**

- Start with 1.25 mg via nebulizer, administer once or twice per day
- May try 2.5 mg if no response with lower dose

Concentration - 1 mg/ml (2.5 ml)

**Chief Indications**

1. Inhaled mucolytic - reduces mucous viscosity
2. Treatment of atelectasis, secondary to mucous plugging, that is unresponsive to conventional therapies.

**Possible Adverse Reactions**

- Desaturation and/or airway obstruction may occur due to rapid mobilization of secretions

**CONTRAINDICATIONS/PRECAUTIONS:**

- Has not been studied in infants/children < 3 years of age

**Nursing Implications**

- Chest physiotherapy should be incorporated into treatment regimen

**Special Considerations and Calculations**

- Should not be mixed with other nebulized medications
- Pulmozyme is supplied in single-use ampoule; each contains 2.5 ml solution containing 1 ml/ml dornase alfa.

References:
1. Neofax 2010

Reviewed/Revised: 03/2011 by

Samir Alabsi, MD
Kelli Cunningham, Pharm. D, BCPS
Rebecca Willson, ARNP, NNP